Compare · ELEV vs MRNA
ELEV vs MRNA
Side-by-side comparison of Elevation Oncology Inc. (ELEV) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELEV and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $96.40B.
- MRNA has hit the wire 13 times in the past 4 weeks while ELEV has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 15 for ELEV).
- Company
- Elevation Oncology Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- -
- $96.40B
- 1M return
- -
- +22.90%
- 1Y return
- -
- +892.52%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 0
- 13
- Recent ratings
- 15
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ELEV
- SEC Form 15-12G filed by Elevation Oncology Inc.
- SEC Form EFFECT filed by Elevation Oncology Inc.
- SEC Form EFFECT filed by Elevation Oncology Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Elevation Oncology Inc.
- SEC Form 4 filed by Director Sandler Alan B.
- SEC Form 4 filed by Director Mootz Darcy
- SEC Form 4 filed by Director Elms Steve
- SEC Form 4 filed by Director Clackson Timothy P
- SEC Form 4 filed by Director Cherrington Julie M
- SEC Form 4 filed by Director Carruthers R Michael
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
- Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting
- Moderna downgraded by William Blair
- A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
- Moderna Named a Top Employer by Science for Twelfth Consecutive Year
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium